Table 1.
Baseline Clinical Characteristics
| Hepatic gene expression (N = 39) | Circulating IGFBP analysis (N = 61) | |
|---|---|---|
| Age (years) | 53 ± 7 | 53 ± 7 |
| % Male | 77 | 79 |
| % Race | ||
| White | 59 | 66 |
| Black | 36 | 30 |
| Other | 5 | 4 |
| % Hispanic | 8 | 15 |
| Duration of HIV-infection (years) | 17 ± 9 | 17 ± 9 |
| CD4 count (cells/mm3) | 758 ± 268 | 765 ± 276 |
| Viral load < 20 copies, mL (%) | 92 | 90 |
| % Current antiretroviral use | ||
| NRTI | 92 | 92 |
| PI | 26 | 25 |
| NNRTI | 36 | 38 |
| Integrase inhibitor | 64 | 64 |
| % Type 2 diabetes | 8 | 13 |
| Body mass index (kg/m2) | 32 ± 6 | 31 ± 6 |
| Hepatic fat fraction (%) | 14 ± 9 | 14 ± 8 |
| Alanine aminotransferase (U/L) | 31 ± 32 | 32 ± 29 |
| Aspartate aminotransferase (U/L) | 31 ± 24 | 32 ± 22 |
| % NASH | 31 | 33 |
| % Fibrosis | 41 | 40 |
| Stage 1 | 15 | 11 |
| Stage 2 | 15 | 18 |
| Stage 3 | 10 | 11 |
| Fasting plasma glucose (mg/dL) | 92 ± 12 | 96 ± 18 |
| Fasting insulin (μU/mL) | 15 ± 17 | 15 ± 15 |
| Hemoglobin A1c (%) | 5.7 ± 0.5 | 5.7 ± 0.5 |
Continuous variables are presented as mean ± standard deviation. Abbreviations: IGFBP, insulin-like growth factor–binding protein; NASH, nonalcoholic steatohepatitis; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.